| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 00003-3774-12 | 00003-3774 | Nivolumab | Opdivo | 10.0 mg/mL | Immunotherapy | Checkpoint Inhibitor | PD-1 | Intravenous | Dec 22, 2014 | In Use | |
| 50242-0933-86 | 50242-0933 | Atezolizumab and hyaluronidase-tqjs | Tecentriq Hybreza | 1875.0 mg/15mL, 30000.0 U/15mL | Immunotherapy | Checkpoint Inhibitor | PD-L1 | Subcutaneous | Sep 12, 2024 | In Use | |
| 83444-0301-10 | 83444-0301 | Cosibelimab | UNLOXCYT | 300.0 mg/5mL | Immunotherapy | Checkpoint Inhibitor | PD-L1 | Intravenous | Jun 30, 2025 | In Use | |
| 00003-3772-11 | 00003-3772 | Nivolumab | Opdivo | 10.0 mg/mL | Immunotherapy | Checkpoint Inhibitor | PD-1 | Intravenous | Dec 22, 2014 | In Use | |
| 00006-3029-02 | 00006-3029 | Pembrolizumab | Keytruda | 50.0 mg/2mL | Immunotherapy | Checkpoint Inhibitor | PD-1 | Intravenous | Sep 4, 2014 | Dec 21, 2015 | In Use |
| 00003-3120-01 | 00003-3120 | Nivolumab and hyaluronidase-nvhy | OPDIVO QVANTIG | 2000.0 U/mL, 120.0 mg/mL | Immunotherapy | Checkpoint Inhibitor | PD-1 | Subcutaneous | Nov 24, 2025 | In Use | |
| 50242-0917-86 | 50242-0917 | Atezolizumab | Tecentriq | 1200.0 mg/20mL | Immunotherapy | Checkpoint Inhibitor | PD-L1 | Intravenous | Aug 11, 2016 | In Use | |
| 00006-5083-01 | 00006-5083 | Pembrolizumab and berahyaluronidase alfa-pmph | KEYTRUDA QLEX | 2000.0 U/mL, 165.0 mg/mL | Immunotherapy | Checkpoint Inhibitor | PD-1 | Subcutaneous | Sep 19, 2025 | In Use | |
| 61755-0008-01 | 61755-0008 | cemiplimab-rwlc | LIBTAYO | 50.0 mg/mL | Immunotherapy | Checkpoint Inhibitor | PD-1 | Intravenous | Sep 28, 2018 | In Use | |
| 50242-0918-86 | 50242-0918 | Atezolizumab | TECENTRIQ | 840.0 mg/14mL | Immunotherapy | Checkpoint Inhibitor | PD-L1 | Intravenous | Mar 8, 2019 | Mar 18, 2019 | In Use |
| 70095-0130-01 | 70095-0130 | Cosibelimab | UNLOXCYT | 300.0 mg/5mL | Immunotherapy | Checkpoint Inhibitor | PD-L1 | Intravenous | Dec 8, 2025 | In Use | |
| 00003-2328-22 | 00003-2328 | Ipilimumab | Yervoy | 5.0 mg/mL | Immunotherapy | Checkpoint Inhibitor | CTLA-4 | Intravenous | Mar 25, 2011 | In Use | |
| 50242-0917-01 | 50242-0917 | Atezolizumab | Tecentriq | 1200.0 mg/20mL | Immunotherapy | Checkpoint Inhibitor | PD-L1 | Intravenous | May 18, 2016 | In Use | |
| 72579-0121-01 | 72579-0121 | Tislelizumab, Tislelizumab-jsgr | TEVIMBRA | 10.0 mg/mL | Immunotherapy | Checkpoint Inhibitor | PD-1 | Intravenous | Mar 14, 2024 | In Use | |
| 00310-4505-25 | 00310-4505 | Tremelimumab | IMJUDO | 25.0 mg/1.25mL | Immunotherapy | Checkpoint Inhibitor | CTLA-4 | Intravenous | Oct 21, 2022 | In Use | |
| 83718-0000-01 | 83718-0000 | Toripalimab-tpzi | LOQTORZI | 240.0 mg/6mL | Immunotherapy | Checkpoint Inhibitor | PD-1 | Intravenous | Oct 27, 2023 | In Use | |
| 50242-0918-01 | 50242-0918 | Atezolizumab | TECENTRIQ | 840.0 mg/14mL | Immunotherapy | Checkpoint Inhibitor | PD-L1 | Intravenous | Mar 8, 2019 | In Use | |
| 00003-2327-11 | 00003-2327 | Ipilimumab | Yervoy | 5.0 mg/mL | Immunotherapy | Checkpoint Inhibitor | CTLA-4 | Intravenous | Mar 25, 2011 | In Use | |
| 00006-3026-04 | 00006-3026 | Pembrolizumab | Keytruda | 25.0 mg/mL | Immunotherapy | Checkpoint Inhibitor | PD-1 | Intravenous | Aug 1, 2019 | In Use | |
| 00003-3734-13 | 00003-3734 | Nivolumab | OPDIVO | 10.0 mg/mL | Immunotherapy | Checkpoint Inhibitor | PD-1 | Intravenous | Dec 8, 2017 | In Use | |
| 25021-0828-50 | 25021-0828 | Leucovorin calcium | Leucovorin Calcium | 500.0 mg/50mL | Ancillary Therapy | Chemoprotective | Antidote | Intramuscular, Intravenous | Apr 15, 2018 | In Use | |
| 68001-0285-36 | 68001-0285 | Leucovorin Calcium | Leucovorin | 10.0 mg/mL | Ancillary Therapy | Chemoprotective | Antidote | Intramuscular, Intravenous | Jul 1, 2016 | Feb 1, 2021 | No Longer Used |
| 00703-5140-01 | 00703-5140 | Leucovorin Calcium | Leucovorin Calcium | 100.0 mg/10mL | Ancillary Therapy | Chemoprotective | Antidote | Intramuscular, Intravenous | Feb 1, 1994 | Sep 30, 2023 | No Longer Used |
| 60687-0227-94 | 60687-0227 | Leucovorin Calcium | Leucovorin Calcium | 25.0 mg/1 | Ancillary Therapy | Chemoprotective | Antidote | Oral | Feb 17, 2017 | In Use | |
| 47781-0622-22 | 47781-0622 | Mesna | Mesna | 100.0 mg/mL | Ancillary Therapy | Chemoprotective | Detoxifying Agent | Intravenous | Mar 29, 2018 | Mar 1, 2020 | In Use |
Found 12393 results — Export these results
Home